1. Home
  2. DLTH vs ADCT Comparison

DLTH vs ADCT Comparison

Compare DLTH & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Duluth Holdings Inc. Class B

DLTH

Duluth Holdings Inc. Class B

HOLD

Current Price

$4.10

Market Cap

138.0M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.09

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLTH
ADCT
Founded
1989
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
136.1M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
DLTH
ADCT
Price
$4.10
$1.09
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$7.00
$7.75
AVG Volume (30 Days)
140.8K
1.5M
Earning Date
06-04-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
64.12
30.86
EPS
0.23
N/A
Revenue
$565,184,000.00
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.80
$66.49
P/E Ratio
$18.52
N/A
Revenue Growth
N/A
14.85
52 Week Low
$2.02
$0.78
52 Week High
$5.09
$4.98

Technical Indicators

Market Signals
Indicator
DLTH
ADCT
Relative Strength Index (RSI) 49.87 46.52
Support Level $3.92 $0.98
Resistance Level $4.71 $1.20
Average True Range (ATR) 0.27 0.09
MACD 0.00 -0.01
Stochastic Oscillator 50.40 25.00

Price Performance

Historical Comparison
DLTH
ADCT

About DLTH Duluth Holdings Inc. Class B

Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: